Biotech Stocks Facing FDA Decision In January 2020

2 / 10
Aimmune Therapeutics
Aimmune Therapeutics

The FDA decision on Aimmune Therapeutics Inc.’s (AIMT) peanut allergy treatment Palforzia is expected to be announced in January.

Peanut allergy, a condition in which the immune system mistakenly recognizes a number of proteins from peanuts as potential foreign pathogens, triggering an inflammation, is most common in children.

Palforzia, formerly known as AR101, is a peanut-derived investigational oral biologic drug that delivers a daily dose of peanut protein.

On September 13, 2019, an FDA panel voted to support the use of Palforzia in children and teens with peanut allergy.

If approved, Palforzia will be the first medicine for peanut allergy. Its market opportunity is estimated to be in excess of $1 billion peak sales in the U.S. alone, according to the Company.

AIMT closed Monday’s (Dec.30, 2019) trading at $33.53, up 2.60%.